nytimes.com/2021/06/10/health/aduhelm-fda-resign-alzheimers.html
The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.
Posted by UE editors
Click to copy the Short Url to this post:
upo.st/cj4p54jy 
The Whole Web on a Single Page, for People Who Love Good Reads. Join Now →